# Amneal Pharmaceuticals share price today (Amneal Pharmaceuticals, Inc., AMRX)

> Amneal Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AMRX · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/amrx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $20.21 (+86.8% in a year)
- P/E: 50.6×, over 4.6 years
- Revenue (Jun 2026): $796 M (+9.9% on a year ago)
- Profit (Jun 2026): $57.7 M (+157.2% on a year ago)
- Operating margin: 18.3% (+2.8 points on a year ago)
- ROE: 1,208%, FY25
- ROIC: 16.1%, against a 9.5% cost of capital: +6.6 points
- Profit that came in as cash: 704%, last 2 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Amneal Pharmaceuticals share price today? Amneal Pharmaceuticals, Inc.'s share price was $20.21 at the close on 3 November 2026. It has been rising for 66 weeks. That is 27.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $22, and at that close it sat 87% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 22 weeks in a row. Over the last 8.5 years the share price moved +37% while the S&P 500 moved +176%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Amneal Pharmaceuticals pay? Amneal Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Amneal Pharmaceuticals on? Amneal Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Amneal Pharmaceuticals profitable? Amneal Pharmaceuticals, Inc. earned $57.7 M of net profit in the Jun 2026 quarter, +157.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $72.1 M. Over 4 years profit has grown 61.4% a year on average. That is 7.2% of the quarter's revenue. The same quarter a year earlier earned $22.4 M. 4 of the last 12 reported quarters were loss-making. ## How much revenue does Amneal Pharmaceuticals make, and is it growing? Amneal Pharmaceuticals, Inc. reported $796 M of revenue in the Jun 2026 quarter, +9.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 9.6% a year on average. The last full year, FY25, came in at $3.0 B. The last four reported quarters add to $3.1 B. FY25 revenue was $3.0 B, +8.0% on the year before. Recent pace: the last four quarters grew +9.3% on average, against 9.6% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.3%, against +9.5% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Amneal Pharmaceuticals keep? Amneal Pharmaceuticals, Inc.'s operating margin was 18.3% in the Jun 2026 quarter, 2.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 9.0% and 13.9%. The latest quarter is above every full year in that period. Across 5 years it has been between 9.0% and 13.9%, and FY25's 13.9% is the highest of them. Why the margin moved: operating margin changed +2.8 percentage points on the year while gross margin changed +2.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Amneal Pharmaceuticals' profit turning into cash? Over the last 2 years, 704% of Amneal Pharmaceuticals, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $340 M of operating cash against $72.1 M of profit. After $98.8 M of spending on assets, $241 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Amneal Pharmaceuticals' cash go? Amneal Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $206 M on assets over the last 3 years. Averaged over those years that is 2.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $206 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Amneal Pharmaceuticals' P/E ratio, and how does it compare with its own history? Amneal Pharmaceuticals, Inc.'s P/E is 50.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +67.6% a year; about +104.4% a year came from earnings growth and about −36.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Amneal Pharmaceuticals business getting better or worse? Amneal Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Amneal Pharmaceuticals earn on its capital? Amneal Pharmaceuticals, Inc. earned a ROE of 1,208% in FY25. That is up from a low of −137% in FY23. Its return on capital used (ROIC) is 6.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 2.4% net margin and 0.82× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 2.4% net margin × 0.82× asset turnover × 616.85× leverage (assets divided by equity) ≈ 1,214.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 16.1% − 9.5% = +6.6 percentage points. The 9.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Amneal Pharmaceuticals have too much debt? Amneal Pharmaceuticals, Inc. has total debt of $2.8 B against shareholder equity of $117 M as of Jun 2026, so its debt is 23.87× its equity. Year by year, that ratio went from 7.52 in FY21 to 450.96 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Amneal Pharmaceuticals shareholding pattern? 6.5% of Amneal Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Amneal Pharmaceuticals from balance-sheet trouble? For Amneal Pharmaceuticals, Inc., the Z-score is 2.06. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.06 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Amneal Pharmaceuticals rank in its industry? 58.2 out of 100, rank 8 of 28 in Drug Manufacturers - Specialty & Generic, with 71% of the evidence available. Amneal Pharmaceuticals, Inc. scores 58.2 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 8. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21 + 14.8 + 9.3 + 13.1 = 58.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Amneal Pharmaceuticals compared with? Amneal Pharmaceuticals ranks 8 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 58.2 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. Amneal Pharmaceuticals, Inc. this page AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Amneal Pharmaceuticals in size? Amneal Pharmaceuticals is the 12th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Dr. Reddy's Laboratories, Alkermes plc and Kiniksa Pharmaceuticals International, plc. Just below it: Lantheus Holdings, Inc., Hims & Hers Health, Inc. and Liquidia Corporation. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Dr. Reddy's Laboratories Limited](https://www.sectoralpha.in/us/stocks/rdy) $12 billion
2. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) $7.7 billion
3. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) $7.3 billion
4. Amneal Pharmaceuticals, Inc. $7 billion
5. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) $6.6 billion
6. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) $6 billion
7. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) $3.8 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) $7.1 billion · Drug Manufacturers - Specialty & Generic
2. [XP Inc.](https://www.sectoralpha.in/us/stocks/xp) $7.1 billion · Capital Markets
3. Amneal Pharmaceuticals, Inc. $7.1 billion
4. [Vornado Realty Trust](https://www.sectoralpha.in/us/stocks/vno) $7.1 billion · REIT - Office
5. [STAG Industrial, Inc.](https://www.sectoralpha.in/us/stocks/stag) $7.1 billion · REIT - Industrial

## What else do people ask about Amneal Pharmaceuticals? ### What is Amneal Pharmaceuticals's stock price today? Amneal Pharmaceuticals, Inc.'s stock price is $20.21, +86.8% over the past year. The whole company is worth $7.0 B on the market. In the last 52 weeks it traded between $11 to $22; today it is 87% of the way up from the low, 27.8% above its 200-day average (as of 3 November 2026). ### What were Amneal Pharmaceuticals's latest quarterly results? Amneal Pharmaceuticals, Inc. reported revenue of $796 M and net profit of $57.7 M for the Jun 2026 quarter. Revenue rose 9.9% and profit rose 157.2% compared with a year earlier. Earnings per share were $0.18. The operating margin was 18.3%, 2.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Amneal Pharmaceuticals's market cap? Amneal Pharmaceuticals, Inc.'s market capitalisation is $7.0 B at a stock price of $20.21. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Amneal Pharmaceuticals performing? Amneal Pharmaceuticals, Inc.'s share price has been rising for 66 weeks. In its latest quarter, revenue rose 9.9% and profit rose 157.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 22 weeks running (as of 3 November 2026). ### Will Amneal Pharmaceuticals's stock price go up? This page does not forecast Amneal Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $20.21, and it has been rising for 66 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Amneal Pharmaceuticals have too much debt? Yes, Amneal Pharmaceuticals, Inc. has a lot of debt: its debt is 5.12× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Is Amneal Pharmaceuticals's profit real cash? Yes, over the last 2 years, 704% of Amneal Pharmaceuticals, Inc.'s reported profit came in as cash from operations. The latest year was lower at 472%, so the trend is worth watching. In FY25, operating cash was $340 M against reported profit of $72.1 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Amneal Pharmaceuticals in its business cycle? Amneal Pharmaceuticals, Inc.'s FY25 operating margin was 13.9%, against a 5-year range of 9.0% to 13.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 18.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Amneal Pharmaceuticals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Amneal Pharmaceuticals a stock worth studying right now? What the numbers show: Amneal Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.